New products provide boost for Animalcare

In a trading update, the company revealed that revenue for the year ended June 30 2011 was around 5 per cent higher than the same period last year.

The four new products launched in the year, along with those launched in late 2009 and early 2010, contributed substantially to this growth, which was also underpinned by a strong performance in the company’s existing ranges, including its fluid therapy and database services.

In a statement, the company said: “Earnings from continuing operations will again show a good progression from the same period last year and are expected to be in line with market expectations.

“Animalcare also announces that it has received notification from the Swedish pharmaceutical contract manufacturing group Recipharm that they will close their steriles production unit at their Recipharm Ashton facility with immediate effect. Due to ongoing production issues this unit had originally been scheduled to close in June 2012. Ashton produces the 1ml ampoule version of Animalcare’s buprenorphine based analgesic, Buprecare. This is the only product supplied to Animalcare from Ashton.

“Animalcare was in the process of establishing alternative manufacturing for Buprecare ahead of the scheduled closure of Ashton steriles production. Efforts are already being made to accelerate the plans already in place to switch production of the Buprecare 1ml ampoule product to an alternative supplier. Unfortunately the premature closure means that there now will be a period during which Animalcare will be unable to supply the 1ml ampoule presentation of Buprecare to the UK market.

“The supply position for the European markets is stronger and any disruption is expected to be minor.”